These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 22162571)

  • 1. Evidence does not support clinically significant lenalidomide-CCI-779 interaction via P-glycoprotein.
    Chen N; Kasserra C; Kumar G; Palmisano M
    J Clin Oncol; 2012 Jan; 30(3):340-1; author reply 341-2. PubMed ID: 22162571
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
    Hofmeister CC; Yang X; Pichiorri F; Chen P; Rozewski DM; Johnson AJ; Lee S; Liu Z; Garr CL; Hade EM; Ji J; Schaaf LJ; Benson DM; Kraut EH; Hicks WJ; Chan KK; Chen CS; Farag SS; Grever MR; Byrd JC; Phelps MA
    J Clin Oncol; 2011 Sep; 29(25):3427-34. PubMed ID: 21825263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients.
    Guglielmelli T; Bringhen S; Rrodhe S; Gay F; Cavallo F; Berruti A; Montefusco V; Piro E; Benevolo G; Petrucci MT; Caravita T; Offidani M; Corradini P; Boccadoro M; Saglio G; Palumbo A
    Eur J Cancer; 2011 Apr; 47(6):814-8. PubMed ID: 21334196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide in multiple myeloma: current role and future directions.
    Zeldis JB; Knight RD; Jacques C; Tozer A; Bizzari JP
    Expert Opin Pharmacother; 2010 Apr; 11(5):829-42. PubMed ID: 20210686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in treatment for relapses and refractory multiple myeloma.
    Richards T; Weber D
    Med Oncol; 2010 Jun; 27 Suppl 1():S25-42. PubMed ID: 20213220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Panobinostat for the treatment of multiple myeloma.
    Rajkumar SV
    Lancet Oncol; 2014 Oct; 15(11):1178-9. PubMed ID: 25242046
    [No Abstract]   [Full Text] [Related]  

  • 7. Histone deacetylase inhibitors in multiple myeloma.
    Pratt G
    Lancet Oncol; 2013 Oct; 14(11):1038-1039. PubMed ID: 24055413
    [No Abstract]   [Full Text] [Related]  

  • 8. Novel agents for relapsed and/or refractory multiple myeloma.
    Thomas SK; Richards TA; Weber DM
    Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The "Next Big Thing" in Treatment for Relapsed or Refractory Multiple Myeloma May Be Held Back by Design-Between the Lines.
    Ruggeri K; Maguire Á; Cook G
    JAMA Oncol; 2016 Nov; 2(11):1405-1406. PubMed ID: 27355621
    [No Abstract]   [Full Text] [Related]  

  • 10. Panobinostat to revert bortezomib resistance.
    Moreau P
    Blood; 2013 Oct; 122(14):2292-3. PubMed ID: 24092922
    [No Abstract]   [Full Text] [Related]  

  • 11. Sequence of novel agents in multiple myeloma: an instrumental variable analysis.
    Baz R; Miladinovic B; Patel A; Ho VQ; Shain KH; Alsina M; Nishihori T; Ochoa-Bayona JL; Sullivan DM; Dalton WS; Djulbegovic B
    Leuk Res; 2013 Sep; 37(9):1077-82. PubMed ID: 23809054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
    Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
    Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of topotecan and cyclophosphamide in patients with relapsed and refractory multiple myeloma.
    Kraut EH; Young D; Farag S; James AG; Solove RJ
    Leuk Res; 2005 Oct; 29(10):1233-4. PubMed ID: 16111541
    [No Abstract]   [Full Text] [Related]  

  • 14. [Carfilzomib in multiple myeloma relapses].
    Bay JO
    Bull Cancer; 2015 Feb; 102(2):116. PubMed ID: 25874287
    [No Abstract]   [Full Text] [Related]  

  • 15. Muscular Relapse in a Patient With Multiple Myeloma.
    Waheed S; Zhu H; Waheed MA; Kumar M; Barlogie B
    J Clin Oncol; 2015 Dec; 33(34):e125-9. PubMed ID: 24778395
    [No Abstract]   [Full Text] [Related]  

  • 16. Prognostic implications of cumulative dosing in total therapy 3.
    Barlogie B; Crowley J
    Blood; 2012 Oct; 120(16):3383-5. PubMed ID: 23086625
    [No Abstract]   [Full Text] [Related]  

  • 17. Pomalidomide in the treatment of relapsed multiple myeloma.
    Forsberg PA; Mark TM
    Future Oncol; 2013 Jul; 9(7):939-48. PubMed ID: 23837756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel combination approaches for myeloma.
    Lonial S; Nooka AK
    Hematology Am Soc Hematol Educ Program; 2015; 2015():286-93. PubMed ID: 26637735
    [No Abstract]   [Full Text] [Related]  

  • 19. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma.
    Bahlis NJ; McCafferty-Grad J; Jordan-McMurry I; Neil J; Reis I; Kharfan-Dabaja M; Eckman J; Goodman M; Fernandez HF; Boise LH; Lee KP
    Clin Cancer Res; 2002 Dec; 8(12):3658-68. PubMed ID: 12473574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current aspects of treatment of multiple myeloma].
    Tribalto M; Avvisati G; Cantonetti M; Catalano G; Giovangrossi P; Masi M; Petrucci MT; Venditti A; Papa G
    Ann Ital Med Int; 1988; 3(3):193-202. PubMed ID: 3152856
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.